The LMO2 Oncogene Regulates DNA Replication in Hematopoietic Cells
The LMO2 oncogene regulates DNA replication in hematopoietic cells Marie-Claude Sincennesa,b,1, Magali Humberta,1, Benoît Grondina, Véronique Lisia,b, Diogo F. T. Veigaa, André Hamana, Christophe Cazauxc,2, Nazar Mashtalird, EL Bachir Affard, Alain Verreaulta,b,e, and Trang Hoanga,b,e,3 aInstitute of Research in Immunology and Cancer, University of Montreal, Montreal, QC, Canada H3C 3J7; bMolecular Biology Program, University of Montreal, Montreal, QC, Canada H1T 2M4; cCancer Research Center of Toulouse, Toulouse 31024, France; dMaisonneuve-Rosemont Hospital Research Center, Department of Medicine, University of Montreal, Montreal, QC, Canada H1T 2M4; and eDepartments of Pharmacology and Biochemistry, University of Montreal, Montreal, QC, Canada H3T 1J2 Edited by Mark Groudine, Fred Hutchinson Cancer Research Center, Seattle, WA, and approved December 2, 2015 (received for review July 30, 2015) Oncogenic transcription factors are commonly activated in acute substitute for LMO1/2 to induce T-ALL, suggesting additional leukemias and subvert normal gene expression networks to reprogram functions for LMO1/2. hematopoietic progenitors into preleukemic stem cells, as exemplified Together, these studies underscore the dominant oncogenic by LIM-only 2 (LMO2) in T-cell acute lymphoblastic leukemia (T-ALL). properties of LMO2, as revealed by recurring retroviral integrations Whether or not these oncoproteins interfere with other DNA-dependent upstream of LMO2 in the gene therapy trial (19, 20) or by recurrent processes is largely unexplored. Here, we show that LMO2 is recruited chromosomal rearrangements in T-ALL (21). As a consequence, to DNA replication origins by interaction with three essential replication LMO2 is misexpressed in the T lineage, where it is normally absent.
[Show full text]